Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis

被引：14

作者：

Toor, Kabirraaj ^{[1
,2
]}

Druyts, Eric ^{[1
,3
]}

Jansen, Jeroen P. ^{[1
,4
]}

Thorlund, Kristian ^{[1
,5
,6
]}

机构：

[1] Redwood Outcomes, Vancouver, BC V6H 3Y4, Canada

[2] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada

[3] Univ British Columbia, Dept Med, Fac Med, Vancouver, BC, Canada

[4] Tufts Univ, Dept Publ Hlth & Community Med, Boston, MA 02111 USA

[5] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada

[6] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA

来源：

JOURNAL OF MEDICAL ECONOMICS | 2015年 / 18卷 / 06期

关键词：

Anti-TNF; Cost; Markov model; Ulcerative colitis;

D O I：

10.3111/13696998.2015.1012513

中图分类号：

F [经济];

学科分类号：

020101 [政治经济学];

摘要：

Objective: To determine the short-term costs per sustained remission and sustained response of three tumor necrosis factor inhibitors (infliximab, adalimumab, and golimumab) in comparison to conventional therapy for the treatment of moderately-to-severely active ulcerative colitis. Methods: A probabilistic Markov model was developed. This included an 8-week induction period, and 22 subsequent 2-week cycles (up to 1 year). The model included three disease states: remission, response, and relapse. Costs were from a Canadian public payer perspective. Estimates for the additional cost per 1 year of sustained remission and sustained response were obtained. Results: Golimumab 100 mg provided the lowest cost per additional remission ($935) and cost per additional response ($701) compared with conventional therapy. Golimumab 50 mg yielded slightly higher costs than golimumab 100 mg. Infliximab was associated with the largest additional number of estimated remissions and responses, but also higher cost at $1975 per remission and $1311 per response. Adalimumab was associated with the largest cost per remission ($7430) and cost per response ($2361). The cost per additional remission and cost per additional response associated with infliximab vs golimumab 100 mg was $14,659 and $4753, respectively. Conclusions: The results suggest that the additional cost of 1 full year of remission and response are lowest with golimumab 100 mg, followed by golimumab 50 mg. Although infliximab has the highest efficacy, it did not exhibit the lowest cost per additional

引用

页码：437 / 446

页数：10

共 23 条

[1]

Dhaens G., Sandborn W.J., Feagan B.G., Et al., A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, 132, pp. 763-786, (2007)

[2]

Reinisch W., Sandborn W.J., Hommes D.W., Et al., Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial, Gut, 60, pp. 780-787, (2011)

[3]

Rutgeerts P., Sandborn W.J., Feagan B.G., Et al., Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, pp. 2462-2476, (2005)

[4]

Sandborn W.J., Feagan B.G., Marano C., Et al., Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, pp. 96-109e101, (2014)

[5]

Danese S., Fiorino G., Peyrin-Biroulet L., Et al., Biological agents for moderately to severely active ulcerative colitis: A systematic review and network metaanalysis, Ann Intern Med, 160, pp. 704-711, (2014)

[6]

Thorlund K., Druyts E., Eapen S., Et al., Comparative efficacy and safety of golimumab, infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis: A Bayesian indirect treatment comparison metaanalysis, Montreal, Canada: International Society for Pharmacoeconomics and Outcomes Research, (2014)

[7]

Thorlund K., Druyts E., Mills E.J., Et al., Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: An indirect treatment comparison meta-analysis, J Crohns Colitis, 80, pp. 571-581, (2014)

[8]

Stidham R.W., Lee T.C., Higgins P.D., Et al., Systematic review with network metaanalysis: The efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis, Alimen Pharmacol Therapeut, 39, pp. 660-671, (2014)

[9]

Regie de Lassurance Maladie du Quebec (RAMQ). Liste de Medicaments No 44, (2013)

[10]

Brereton N., Bodger K., Kamm M.A., Et al., A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective, J Med Econ, 13, pp. 148-161, (2011)

← 1 2 3 →